For several years, experimental wellness peptides have occupied an uneasy corner of the drug market. In 2023, the FDA identified significant safety concerns with several substances being nominated for pharmacy compounding. Consumers could still find many of them through websites selling vials labeled for research use only. Now one of the largest names in consumer telehealth wants to bring peptide treatments into a more conventional healthcare setting.
Hims & Hers says it will launch Peptides+ in November 2026, initially offering sermorelin, glutathione and NAD+, with other treatments planned later. The announcement followed a new Department of Health and Human Services policy providing limited enforcement discretion for pharmacies compounding six specified peptide substances. The two developments are connected, but they are not identical: the first Hims products are not among the six substances covered by the new policy.
The central question is what oversight customers can expect. The HHS policy requires specified testing documentation for bulk peptide ingredients, and licensed pharmacies remain subject to applicable quality and safety requirements. But compounded drugs are not FDA-approved, and the agency does not review each formulation for safety, effectiveness and quality before it reaches patients.
That is the gap Hims is entering: more formal safeguards than the research-only market, without the clinical and regulatory evidence associated with an approved medicine.
What Hims Is Selling, and When
Chief executive Andrew Dudum previewed Peptides+ in an October 29 company post, one day after HHS announced its interim compounding policy. Hims listed sermorelin, glutathione, vitamin B12, NAD+ and L-carnitine among its planned offerings. It said BPC-157 and TB-500 would follow when the regulatory environment allowed.
The company described a model involving independent healthcare providers, personalized treatment plans, licensed pharmacies and continuing clinical support. Dudum acknowledged the limits of the evidence, writing that published studies remain limited for many of these compounds and that important questions remain unanswered.
On its November 9 earnings call, Hims became more specific. The initial phase, expected later in November, would include sermorelin, glutathione and NAD+. Management again said BPC-157 and TB-500 would come later, subject to the regulatory situation.
Reuters reported the same three-product launch plan on November 9. Chief financial officer Yemi Okupe said the new treatments were expected to contribute an immaterial amount of revenue during 2026. The rollout is therefore an expansion strategy rather than an immediate financial transformation.
There is an important distinction within the product list. Sermorelin is a peptide, glutathione is a three-amino-acid peptide, and NAD+ is a coenzyme. Vitamin B12 and L-carnitine are not peptides. Peptides+ is a commercial category that groups several kinds of compounds together, not a list of chemically identical products.
The Policy Underneath: What HHS Actually Requires
The new HHS policy covers six substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Published in the Federal Register on October 30, it states that HHS does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities and licensed physicians compounding these substances while the FDA’s formal rulemaking continues, provided specified conditions are met.
That is enforcement discretion, not FDA approval. The substances have not been added to the agency’s permanent list of bulk drug ingredients eligible for compounding, and the department says the policy can be revisited if safety or quality problems emerge.
Crucially, the policy is not an invitation to compound untested powder from an unknown supplier. It calls for bulk peptide ingredients from FDA-registered manufacturers, with valid certificates of analysis documenting testing for identity, purity, potency and contaminants. Its conditions include manufacturer verification, specific permitted dosage forms and administration routes, reporting of serious adverse events and product-quality issues, and compliance with other applicable drug laws.
The policy also specifies that covered compounded products contain only one of the six listed active pharmaceutical ingredients. It requires patient-specific prescriptions and says oral formulations must have documentation supporting adequate bioavailability in humans.

Ingredient Testing Is Not the Same as Testing a Finished Medicine
The distinction matters because several different questions are routinely compressed into the word “tested.”
A manufacturer can analyze a bulk peptide ingredient to establish its identity, purity, strength and contamination profile. A compounding pharmacy can then use that ingredient to prepare a patient-specific medicine. But those steps do not, by themselves, demonstrate that every finished formulation has the stability, consistency or clinical effects of an FDA-approved drug.
Compounded medicines remain subject to applicable pharmacy standards, state oversight and federal restrictions, including prohibitions on insanitary conditions. The new policy also introduces reporting mechanisms intended to help regulators identify emerging problems. It would therefore be inaccurate to say compounded peptides face no testing or regulation.
What remains absent is the standard FDA premarket review required for approved medicines. The agency has not evaluated the safety and effectiveness of these individual compounded treatments for the wellness uses being promoted.
A certificate showing what is in a bulk ingredient cannot establish whether the resulting treatment works in people.
In a November 13 analysis republished by Fortune, Villanova University law professor Ana Santos Rutschman argued that broader access could expose patients to poorly understood risks and reduce incentives to run the clinical studies needed to evaluate these substances.
Her broader concern is supported by the regulatory distinction. Compounding can address individual patient needs, but it does not substitute for controlled clinical trials of a new medicine. HHS believes the interim policy will move patients away from less transparent research-only suppliers and into a more controlled setting. Whether that produces better safety outcomes remains an empirical question.
Not All the Peptides Have the Same Evidence
It is also necessary to separate Hims’ first offerings from the compounds attracting the most attention online.
Sermorelin is a synthetic peptide that stimulates the release of growth hormone through growth hormone-releasing hormone receptors. Glutathione is a naturally occurring antioxidant composed of three amino acids. NAD+ is a coenzyme involved in cellular energy metabolism. Their chemical identities and biological roles do not establish that compounded wellness treatments using them deliver the broad benefits often associated with longevity, recovery or improved energy.
BPC-157 and TB-500 occupy a different position. Both have developed strong followings in online fitness and recovery communities, where they are sometimes promoted together as the “Wolverine stack.” Claims about injury recovery and tissue repair have outpaced the available clinical evidence.
The HHS policy itself acknowledges human research and other evidence relevant to its interim decision, but that should not be confused with successful large clinical trials establishing approved therapeutic indications. The presence of limited human studies does not settle questions about optimal formulations, long-term safety or effectiveness for particular conditions.
There is another practical complication: Hims has not publicly explained, product by product, the complete regulatory and formulation basis for every treatment planned under Peptides+. The six-substance HHS policy does not automatically authorize sermorelin, glutathione, NAD+ or the other products in its initial lineup.
Why a Hims Launch Changes the Stakes
Scale changes how an experimental category reaches consumers. Hims reported approximately 2.8 million subscribers in the third quarter of 2026. A treatment offered through a polished app, an online medical consultation and a licensed pharmacy may feel more familiar and credible than a vial obtained from a research-use-only website.
That difference could be valuable if it moves consumers toward legitimate medical oversight and stronger sourcing standards. It also creates a communication responsibility. A prescription, professional-looking packaging and a recognizable brand do not mean a compounded product has undergone FDA approval.
Hims says it has invested in a U.S. peptide manufacturing facility in Menlo Park, California. On the November 9 call, Dudum said the company intends to manufacture active ingredients for future BPC-157 and TB-500 products domestically because it is concerned about the quality of existing supply chains.
He also said the company was developing clinical standards and laboratory-testing arrangements for Peptides+. These statements indicate planned oversight, not an absence of testing. But the company announcements reviewed for this article do not provide a public product-by-product account of finished-formulation specifications, batch-release testing results or independent verification.
That is the information needed to assess how far the company’s approach goes beyond the minimum regulatory framework.
The Business Case Behind Peptides+
There is an economic reason Hims wants a broader selection of treatments. Its third-quarter gross margin fell from 74% in 2025 to 57% in 2026. The company attributed substantial pressure to a changing product mix, including greater use of branded weight-loss medicines and other operating changes.
Grey Pepper previously examined that transition in its report on Hims’ earnings and the shift in its GLP-1 business.
A broader portfolio of cash-pay treatments, supported by Hims’ own manufacturing and fulfillment infrastructure, could improve the economics over time. That is a plausible business incentive, not proof of the profitability or effectiveness of Peptides+ itself.
Management has said the initial category will make little difference to 2026 revenue. For now, the more important objective appears to be expanding the number of treatments available to existing customers and strengthening relationships that extend beyond weight loss.
What Regulators and Patients Should Watch Next
Several questions remain unanswered.
First is the final status of the six peptides covered by the interim HHS policy. The department has not permanently added them to the section 503A bulks list, and the FDA’s rulemaking may produce a different long-term outcome. As Grey Pepper previously explained in its report on the six-peptide enforcement-discretion policy, temporary federal enforcement restraint is not equivalent to permanent authorization or approval.
Second is Hims’ public documentation. The company has described investment in manufacturing and clinical oversight, but detailed public evidence of the testing procedures and results for individual marketed formulations would help consumers and clinicians evaluate those claims.
Third is the clinical evidence. For experimental compounds, the important questions remain whether a particular formulation improves a defined health outcome, how frequently adverse effects occur and whether benefits persist with longer use. Ingredient certificates and adverse-event reporting cannot answer those questions on their own.
Finally, there is the question of how treatments will be marketed. Claims about cellular resilience, recovery, energy or longevity need to be distinguished from outcomes established in clinical trials. The distinction becomes more important as these products move from small research-oriented sellers to large direct-to-consumer healthcare platforms.
The Test of a More Trustworthy Market
HHS argues that its interim policy can offer a more controlled alternative to the research-only peptide market. That is a reasonable regulatory objective, and its sourcing, documentation and reporting conditions should not be ignored. Hims, meanwhile, says it wants to bring the category into clinician-supervised care with additional manufacturing oversight.
The unresolved question is how these safeguards translate into evidence about the finished medicines patients actually receive. Quality testing can help identify whether a substance meets specified chemical requirements. It cannot, without clinical research, establish whether a treatment is effective or sufficiently safe for routine use.
If Hims wants Peptides+ to be the more trustworthy version of a fragmented market, the clearest opportunity is transparency: identify who makes each treatment, explain the testing standards, publish meaningful quality information and communicate the limits of the clinical evidence.
For now, the company is preparing to launch a new category. The six-peptide policy offers a temporary regulatory pathway for some future products, with genuine quality-related conditions but without FDA approval.
A familiar healthcare brand can make an experimental treatment look established. The evidence still has to earn that confidence.
Disclosure: Grey Pepper’s owner also has business interests in the research-peptide market.
Sources
- Hims & Hers Newsroom — Expanding Safe Access to Peptides, Andrew Dudum, October 29, 2026.
- U.S. Department of Health and Human Services — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, October 2026.
- Federal Register — Notice of Availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, October 30, 2026.
- Hims & Hers — Third Quarter 2026 Earnings Call Transcript, November 9, 2026.
- Hims & Hers Investor Relations — Third Quarter 2026 Financial Results, November 9, 2026.
- Reuters — Hims & Hers to Offer Peptides as Soon as November After US Eases Curbs, November 9, 2026.
- Fortune / The Conversation — Ana Santos Rutschman on the HHS Peptide Compounding Policy, November 13, 2026.
- Venable LLP — In-Depth Analysis of the HHS Interim Peptide Compounding Policy, November 2026.

